Telcon Inc - Asset Resilience Ratio
Telcon Inc (200230) has an Asset Resilience Ratio of 3.83% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Telcon Inc (200230) financial obligations for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2013–2024)
This chart shows how Telcon Inc's Asset Resilience Ratio has changed over time. See Telcon Inc shareholders equity for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Telcon Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Telcon Inc stock valuation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩6.00 Billion | 3.83% |
| Total Liquid Assets | ₩6.00 Billion | 3.83% |
Asset Resilience Insights
- Limited Liquidity: Telcon Inc maintains only 3.83% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Telcon Inc Industry Peers by Asset Resilience Ratio
Compare Telcon Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Yabao Pharmaceutical Group Co Ltd
SHG:600351 |
Drug Manufacturers - Specialty & Generic | 0.27% |
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276 |
Drug Manufacturers - Specialty & Generic | 0.16% |
|
Sandoz Group AG
SW:SDZ |
Drug Manufacturers - Specialty & Generic | 6.43% |
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI |
Drug Manufacturers - Specialty & Generic | 1.54% |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 6.40% |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
Annual Asset Resilience Ratio for Telcon Inc (2013–2024)
The table below shows the annual Asset Resilience Ratio data for Telcon Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 4.38% | ₩6.73 Billion ≈ $4.56 Million |
₩153.59 Billion ≈ $104.08 Million |
-3.10pp |
| 2023-12-31 | 7.49% | ₩10.51 Billion ≈ $7.12 Million |
₩140.41 Billion ≈ $95.16 Million |
-2.54pp |
| 2022-12-31 | 10.03% | ₩11.96 Billion ≈ $8.10 Million |
₩119.25 Billion ≈ $80.82 Million |
-3.77pp |
| 2021-12-31 | 13.80% | ₩23.19 Billion ≈ $15.72 Million |
₩168.03 Billion ≈ $113.87 Million |
+0.44pp |
| 2020-12-31 | 13.36% | ₩24.73 Billion ≈ $16.76 Million |
₩185.05 Billion ≈ $125.41 Million |
+1.30pp |
| 2019-12-31 | 12.07% | ₩15.88 Billion ≈ $10.76 Million |
₩131.65 Billion ≈ $89.22 Million |
+8.01pp |
| 2018-12-31 | 4.05% | ₩7.36 Billion ≈ $4.99 Million |
₩181.79 Billion ≈ $123.20 Million |
-10.25pp |
| 2017-12-31 | 14.30% | ₩29.98 Billion ≈ $20.32 Million |
₩209.64 Billion ≈ $142.07 Million |
+5.58pp |
| 2016-12-31 | 8.72% | ₩10.86 Billion ≈ $7.36 Million |
₩124.51 Billion ≈ $84.38 Million |
+8.62pp |
| 2015-12-31 | 0.10% | ₩50.00 Million ≈ $33.88K |
₩48.15 Billion ≈ $32.63 Million |
-12.87pp |
| 2014-12-31 | 12.97% | ₩6.20 Billion ≈ $4.20 Million |
₩47.76 Billion ≈ $32.37 Million |
+6.27pp |
| 2013-12-31 | 6.71% | ₩2.16 Billion ≈ $1.46 Million |
₩32.20 Billion ≈ $21.82 Million |
-- |
About Telcon Inc
TELCON RF PHARMACEUTICAL. Inc. primarily engages in the development, production, and sale of RF coaxial connectors worldwide. It also provides coaxial couplers, distributors, and arresters, as well as cable assemblies; and pharmaceuticals. The company was formerly known as Telcon Co., Ltd. TELCON RF PHARMACEUTICAL. Inc. was founded in 1999 and is headquartered in Yongin-si, South Korea.